Core A is responsible for the identification and enrollment of every adult patient referred to the Siteman Cancer Center with newly diagnosed and relapsed acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS). The clinical and pathologic material from these patients are entered into databases that are required for the execution of this program project. Additionally, clinical, pathologic and therapeutic information are essential for determining the clinical relevance of a newly identified genetic mutation. The Clinical Database Core (Core A) was established in 2002 to serve as a platform for the investigation of genetic mutations associated with the pathogenesis of MDS and acute myeloid leukemia, and has two Specific Aims, as follows:
Specific Aim 1 : We will prospectively identify and enroll on study all patients with newly diagnosed or relapsed AML and MDS referred to Washington University Siteman Cancer Center. Since its establishment, Core A has been responsible for banking tissue from 167 MDS and 387 AML patients (-98% accrual) according to an IRB approved Tissue Acquisition protocol. From these 554 patients, bone marrow was collected from 515 (93%), blood from 517 (93%), serum from 455 (82%), skin from 495 (89%), and oral mucosa cells from 376 (68%), as of 4/1/07. Additional tumor specimens were collected from 28 of the AML patients at the time of relapse/progression;additional tumor specimens were collected from 13 of the MDS patients at the time of progression to AML. Since January of 2007, 43 patients have been reconsented so that their samples can be used for the whole genome resequencing studies of Project 1.
Specific Aim 2 : We will establish a comprehensive clinical leukemia database that will capture epidemiological data, disease-related characteristics, prognostic factors, therapeutic information, and outcomes from all newly diagnosed and relapsed AML and MDS patients referred to Siteman Cancer Center. Along with genomic data obtained on specimens collected from these patients and stored in the Specimen Acquisition and Expression Profiling Core (Core B), this comprehensive database will provide the Project 2 and the Biostatistics Core (Core C) with critical elements to test and validate the prognostic significance of any given mutation. Comprehensive disease-specific and outcomes data has been compiled on every patient in a de-identified database. This effort has facilitated the compilation of a well defined and uniform set of 94 samples from patients with de novo AML (primarily MO-M4) with >30% blasts, <2 clonal cytogenetic abnormalities, and with adequate tumor and germline DMA specimens for DMA sequence analysis, array-based genomic studies to define copy number changes and uniparental disomy, and arraybased gene expression profiling.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA101937-09
Application #
8375669
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
2012-04-01
Project End
2013-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
9
Fiscal Year
2012
Total Cost
$153,762
Indirect Cost
$42,544
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Fisher, D A C; Malkova, O; Engle, E K et al. (2017) Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia 31:1962-1974
Uy, G L; Duncavage, E J; Chang, G S et al. (2017) Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia 31:872-881
Cole, Christopher B; Russler-Germain, David A; Ketkar, Shamika et al. (2017) Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. J Clin Invest 127:3657-3674
Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13
Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558
Duncavage, Eric J; Uy, Geoffrey L; Petti, Allegra A et al. (2017) Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood 129:1397-1401
Shirai, Cara Lunn; White, Brian S; Tripathi, Manorama et al. (2017) Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun 8:14060
Schroeder, Mark A; Choi, Jaebok; Staser, Karl et al. (2017) The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant :
Zhang, Jin; Griffith, Malachi; Miller, Christopher A et al. (2017) Comprehensive discovery of noncoding RNAs in acute myeloid leukemia cell transcriptomes. Exp Hematol 55:19-33
Ali, Alaa M; Weisel, Daniel; Gao, Feng et al. (2017) Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer Med 6:2814-2821

Showing the most recent 10 out of 113 publications